Haferlach et al developed a new prognostic score for patients with acute myeloid leukemia (AML). This can help identify patients who may require more aggressive management. The authors are from the German AML Cooperative Group.
Patient selection: de novo diagnosis of AML and age > 16 years
Parameters:
(1) prognostic group based on cytogenetics
(2) bone marrow blasts on day 16 after starting therapy
Cytogenetic Findings |
Prognostic Group |
---|---|
t(8;21) or t(16;16) or inv(16) |
favorable |
normal or not in favorable or unfavorable group |
intermediate |
aberrations in chromosome 5, chromosome 7, 11q23, 12p, or 17p |
unfavorable |
inv(3) or t(3;3) |
unfavorable |
>=3 chromosomes involved (complex aberrant) |
unfavorable |
Prognostic Group |
Bone Marrow Blasts |
Group |
---|---|---|
favorable |
|
1 |
intermediate |
< 10% |
2 |
intermediate |
>= 10% |
3 |
unfavorable (not complex aberrant) |
|
4 |
unfavorable (complex aberrant) |
|
5 |
Group |
Median Overall Survival from 1999 Study |
Complete Response to Therapy |
---|---|---|
1 |
25 months |
63% |
2 |
15 months |
65% |
3 |
12 months |
51% |
4 |
6 months |
45% |
5 |
4 months |
35% |
where:
• The overall survival data makes merging Groups 2+3 and 4+5 attractive.
Purpose: To evaluate a patient with AML using the prognostic score of Haferlach et al.
Specialty: Hematology Oncology
Objective: risk factors, severity, prognosis, stage, complications, selection
ICD-10: C92,